Last reviewed · How we verify

local infiltration of liposomal bupivacaine

TriHealth Inc. · FDA-approved active Small molecule

local infiltration of liposomal bupivacaine is a Local anesthetic (amide class) Small molecule drug developed by TriHealth Inc.. It is currently FDA-approved for Local infiltration anesthesia for surgical procedures, Postoperative pain management via local infiltration.

Liposomal bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes to prevent pain signal transmission, with extended duration due to liposomal encapsulation.

Liposomal bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes to prevent pain signal transmission, with extended duration due to liposomal encapsulation. Used for Local infiltration anesthesia for surgical procedures, Postoperative pain management via local infiltration.

At a glance

Generic namelocal infiltration of liposomal bupivacaine
SponsorTriHealth Inc.
Drug classLocal anesthetic (amide class)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia / Pain Management
PhaseFDA-approved

Mechanism of action

Bupivacaine is an amide-class local anesthetic that inhibits sodium influx through voltage-gated sodium channels in nerve fibers, thereby preventing depolarization and action potential propagation. The liposomal formulation provides sustained release of the active drug, extending the duration of anesthesia at the infiltration site compared to conventional bupivacaine solutions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about local infiltration of liposomal bupivacaine

What is local infiltration of liposomal bupivacaine?

local infiltration of liposomal bupivacaine is a Local anesthetic (amide class) drug developed by TriHealth Inc., indicated for Local infiltration anesthesia for surgical procedures, Postoperative pain management via local infiltration.

How does local infiltration of liposomal bupivacaine work?

Liposomal bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes to prevent pain signal transmission, with extended duration due to liposomal encapsulation.

What is local infiltration of liposomal bupivacaine used for?

local infiltration of liposomal bupivacaine is indicated for Local infiltration anesthesia for surgical procedures, Postoperative pain management via local infiltration.

Who makes local infiltration of liposomal bupivacaine?

local infiltration of liposomal bupivacaine is developed and marketed by TriHealth Inc. (see full TriHealth Inc. pipeline at /company/trihealth-inc).

What drug class is local infiltration of liposomal bupivacaine in?

local infiltration of liposomal bupivacaine belongs to the Local anesthetic (amide class) class. See all Local anesthetic (amide class) drugs at /class/local-anesthetic-amide-class.

What development phase is local infiltration of liposomal bupivacaine in?

local infiltration of liposomal bupivacaine is FDA-approved (marketed).

What are the side effects of local infiltration of liposomal bupivacaine?

Common side effects of local infiltration of liposomal bupivacaine include Injection site reactions, Systemic toxicity (rare, dose-dependent), Transient paresthesia.

What does local infiltration of liposomal bupivacaine target?

local infiltration of liposomal bupivacaine targets Voltage-gated sodium channels and is a Local anesthetic (amide class).

Related